Robin Isaacs

5.2k citations
40 papers · 2.9k · 2 hit papers · h-index 25

Impact in

  • Virology top 0.5%
    • HIV Research and Treatment
    • HIV/AIDS drug development and treatment
    • HIV/AIDS Research and Interventions

Papers in

    • HIV/AIDS drug development and treatment 12
    • Antimicrobial Resistance in Staphylococcus 3
    • Antibiotics Pharmacokinetics and Efficacy 10

Robin Isaacs

40 papers receiving 2.8k citations

Robin Isaacs's Hit Papers

Efficacy and safety of sulbactam–durlobactam versus colistin for the treatment of patients with serious infections caused by Acinetobacter baumannii–calcoaceticus complex: a multicentre, randomised, active-controlled, phase 3, non-inferiority clinical trial (ATTACK) 2023 · 176 citations
1760+6+12Years since publication100200300400

Peers

Robin Isaacs
Comparison fields: 5 of 103
  • Virology 1.1k
  • Infectious Diseases 1.7k
  • Molecular Medicine 380
  • Applied Microbiology and Biotechnology 105
  • Parasitology 154
Replace B. Marchou with:
B. Marchou France
Helmut Albrecht United States
Ploenchan Chetchotisakd Thailand
Bruce L. Gilliam United States
Richard Hafner United States
Lawrence J. Eron United States
Hedy Teppler United States
Fredy Suter Italy
J Modaï France
Simon Portsmouth United States
Robin Isaacs relative to B. Marchou France B. Marchou's profile →
Citations per field
00.5×6.2×
B. Marchou · 1×
Citations per year

Countries citing papers authored by Robin Isaacs

Since Specialization
Citations

This map shows the geographic impact of Robin Isaacs's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Robin Isaacs with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Robin Isaacs more than expected).

Fields of papers citing papers by Robin Isaacs

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Robin Isaacs. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Robin Isaacs. The network helps show where Robin Isaacs may publish in the future.

Co-authors

The 25 scholars most cited alongside Robin Isaacs, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.

Border = papers with Robin Isaacs Line = papers co-authored together Robin Isaacs links everyone, so they are left out of the graph.

All Works

20 of 20 papers shown

Showing the 20 most-cited of 40 papers — load more, or switch the sort, to bring in the rest.

#Work
1
Safety and efficacy of the HIV-1 integrase inhibitor raltegravir (MK-0518) in treatment-experienced patients with multidrug-resistant virus: a phase II randomised controlled trial
Hit paper breakdown →
2007452
2 2007319
3 2006293
4 1998207
5
Efficacy and safety of sulbactam–durlobactam versus colistin for the treatment of patients with serious infections caused by Acinetobacter baumannii–calcoaceticus complex: a multicentre, randomised, active-controlled, phase 3, non-inferiority clinical trial (ATTACK)
Hit paper breakdown →
2023176
6 2000154
7 1991132
8 2001122
9 200994
10 199494
11 200969
12 201863
13
Ciprofloxacin resistance in epidemic methicillin-resistant Staphylococcus aureus.
198860
14 200255
15 201954
16 201053
17 200350
18 198947
19 201141
20 201937

About Robin Isaacs

Robin Isaacs is a scholar working on Infectious Diseases, Pharmacology, Epidemiology, Molecular Medicine and Molecular Biology, having authored 40 papers that have together received 2.9k indexed citations. Recurring topics across this work include HIV/AIDS drug development and treatment (12 papers), Antibiotics Pharmacokinetics and Efficacy (10 papers), Antibiotic Resistance in Bacteria (9 papers), Pneumonia and Respiratory Infections (4 papers), Antibiotic Use and Resistance (3 papers), Antimicrobial Resistance in Staphylococcus (3 papers), HIV Research and Treatment (3 papers) and Vector-borne infectious diseases (2 papers). The work is most often cited by research in Virology (1.1k citations), Infectious Diseases (1.7k citations), Molecular Medicine (380 citations), Applied Microbiology and Biotechnology (105 citations) and Parasitology (154 citations). Robin Isaacs has collaborated with scholars based in United States, New Zealand and Japan. Frequent co-authors include Charles J. Gonzalez, Hedy Teppler, Bach‐Yen Nguyen, Charlotte M. Harvey, Larissa Wenning, Javier O Morales-Ramirez, Colin Kovacs, John P. O’Donnell, Christine Katlama and Adriano Lazzarin. Their work appears in journals such as Antimicrobial Agents and Chemotherapy, JAIDS Journal of Acquired Immune Deficiency Syndromes, Journal of Clinical Oncology, Journal of Antimicrobial Chemotherapy and Infection and Immunity.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact